CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC ACQUIRES ONCOLOGY PRODUCT CANDIDATES

Cambridge Antibody Technology is buying two experimental cancer drugs from a unit of Denmark's Danisco for up to $16 million to boost its drugs pipeline, the UK biotech firm said on Tuesday. CAT said it was buying GCR-3888, which is in intermediate Phase II clinical trials for hairy cell leukemia (HCL), and GCR-8015, a preclinical treatment for cancers including non-Hodgkin's lymphoma, from Danisco's Genencor unit.

ABC News (http://abcnews.go.com/Health/wireStory?id=1269632)